We choose indications by asking ourselves, “What problems are patients facing that need to be solved?”. Then, we use our scientific insights combined with our proprietary platform to highlight opportunities outside commonly-practiced approaches.
Spinal Muscular Atrophy
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Commercialization
Apitegromab (selective anti-latent myostatin)
Anticipated Key Milestones
Commercial Launch 2025*
Apitegromab (Myostatin-Related Disorders)
Myostatin-Related Disorders
Next Anticipated Milestone: Identify second indication for apitegromab
Target: Pro/Latent Myostatin
Description: Myostatin-Related Disorders
Cardiometabolic Disorders
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Commercialization
Apitegromab in Obesity**
Anticipated Key Milestones
EMBRAZE Ph 2 POC data expected in Q2 2025
SRK-439 (novel antimyostatin antibody)
Anticipated Key Milestones
File IND in 2025
Immuno-Oncology
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Commercialization
SRK-181 (Selective context-independent, anti-latent TGFβ-1)
Anticipated Key Milestones
Rolling clinical data updates
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Commercialization
Selective context-dependent (LTBP1 & LTBP3) anti-latent TGFβ-1
Anticipated Key Milestones
IND-enabling studies
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Commercialization
Selective anti-RGMc
Anticipated Key Milestones
IND-enabling studies
LTBP3=latent transforming growth factor beta binding protein 3; LTBP1=Latent Transforming Growth Factor Beta Binding Protein 1; RGM=Repulsive guidance molecule; TGFβ-1 =Transforming Growth Factor Beta-1; IND = Investigational New Drug; POC = Proof of Concept
* Contingent upon receipt of regulatory approval; ** Subject to receipt of regulatory authority approval, we plan to utilize data from a previously completed Ph 1 study in healthy volunteers and initiate a Ph 2 POC trial in 2024.
Clinical Trials
We focus on the discovery and development of safe and effective therapies to find optimal solutions for those who need it.
Partnerships
Help us shed light on the subject. Collaborate with us to uncover enlightened solutions for patients.